RecruitingPhase 2NCT04925648

Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction

PICAASO / CA180-722: Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction

Sponsor

St Vincent's Hospital, Sydney

Enrollment

22 participants

Start Date

Oct 18, 2021

Study Type

INTERVENTIONAL

Conditions

Metastatic Prostate Cancer

Summary

The study's purpose is to understand the appearance of your prostate-specific membrane antigen (PSMA) PET scan after you take 14 days of treatment with a drug called dasatinib alone or in combination with anti-testosterone drug call darolutamide. Who is it for? You may be eligible to join this study if you have metastatic prostate cancer and had a recent PSMA scan showing low PSMA uptake Study Details: Participants will receive dasatinib 100 mg daily or dasatinib 100 mg daily and darolutamide 600 mg twice daily for 14 days. They will undergo another PSMA PET scan after 14 days. Participants will be followed up on day 7 of treatment and 30 days after treatment. It is hoped that this research will provide insight into the mechanism of PSMA expression in advanced prostate cancer.

Eligibility

Sex: MALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether two drugs — dasatinib and darolutamide — can boost the effectiveness of a targeted radiation therapy called PSMA theranostics in men with advanced prostate cancer that has stopped responding to standard hormone treatments. **You may be eligible if...** - You are male and at least 18 years old - You have confirmed prostate cancer that has spread and no longer responds to hormone therapy (castrate-resistant) - Your cancer has been shown on special scans (PSMA and FDG PET) to be a poor candidate for PSMA-targeted radiation therapy - Your testosterone levels are very low (castrate levels) **You may NOT be eligible if...** - You have previously taken dasatinib for any reason - You are allergic to dasatinib or darolutamide - You have had a pleural effusion (fluid around the lung) in the last 6 months - You take certain heart or stomach medications that interact with dasatinib - You have had a heart attack, severe heart failure, or irregular heartbeats within the last 6 months Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.